Judah Frommer

Q: What is Judah Frommer's success rate?

Judah Frommer currently has a success rate of 69.52726458357685.

Q: What is the average return of Judah Frommer's calls?

Their stock ratings have generated an average return of 19.566353369857445.

Morgan Stanley | Healthcare

Judah Frommer is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1960 out of 4620 analysts, they have issued 19 stock ratings with a success rate of 69.53% and an average return of 19.57%.

With 19 ratings to date, Judah Frommer is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 69.53% and an average return of 19.57%, highlighting promising potential as their track record develops further.

#1960

Out of 4620

Total Ratings

+69.53%

Success Rate

+19.57%

Average Return

Recent Ratings Analysis

KLRS

Buy

Apr 16, 2026

Target

$14.00

Current

$5.82

Performance

—

Judah Frommer rated KLRS as Overweight on Apr 16, 2026, setting a price target of 14. Shares have remained stable near 5.82, leaving the 14 target still in play.

IMMX

Buy

Mar 25, 2026

Target

$20.00

Current

$9.85

Performance

10.55%

On Mar 25, 2026, IMMX was given a Overweight rating by Judah Frommer, with a target price of 20. The stock rallied 10.55% after the rating, narrowing the gap to the target of 20 and validating the bullish stance.

TRVI

Buy

Mar 18, 2026

Target

$18.00

Current

$14.04

Performance

31.34%

TRVI received a Overweight rating from Judah Frommer on Mar 18, 2026, aiming for 18. Momentum has favored the Buy call, with shares climbing from 14.04 to 14.04, rewarding those who trusted the recommendation.

ZBIO

Hold

Mar 17, 2026

Target

$21.00

Current

$21.34

Performance

-9.11%

On Mar 17, 2026, Judah Frommer published a Equal-Weight outlook on ZBIO, with a target of 21. Weakness in the stock, now at 21.34, supported the conservative rating.

RGNX

Buy

Mar 06, 2026

Target

$18.00

Current

$9.30

Performance

7.51%

Judah Frommer on Mar 06, 2026 assigned RGNX a Overweight rating, with a price target of 18. The Buy call aligned well with market performance, producing a gain of 7.51%.

AGMB

Buy

Mar 03, 2026

Target

$28.00

Current

$10.47

Performance

-34.15%

On Mar 03, 2026, Judah Frommer reaffirmed AGMB with a Overweight rating, targeting 28. Shares slid 34.15% despite the recommendation, highlighting downside risks.

BLTE

Buy

Mar 03, 2026

Target

$201.00

Current

$171.93

Performance

2.41%

BLTE was rated Overweight by Judah Frommer on Mar 03, 2026, with a price objective of 201. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

GMAB

Hold

Feb 16, 2026

Target

$34.00

Current

$29.06

Performance

—

On Feb 16, 2026, Judah Frommer initiated coverage on GMAB with a Equal-Weight rating and target of 34. The stock’s lack of movement around 29.06 aligned with a cautious approach.

ABVX

Buy

Jan 09, 2026

Target

$145.00

Current

$125.80

Performance

9.97%

Judah Frommer issued a Overweight recommendation for ABVX on Jan 09, 2026, price target set at 145. Investors following the Buy call captured upside momentum, with shares now at 125.8.

EVMN

Buy

Dec 01, 2025

Target

$36.00

Current

$26.63

Performance

27.36%

On Dec 01, 2025, EVMN was evaluated by Judah Frommer, who gave a Overweight rating and target of 36. This case illustrates how a timely bullish rating can translate into tangible gains of 27.36%.

APLS

Hold

Jul 02, 2025

Target

$26.00

Current

$40.85

Performance

129.24%

Judah Frommer rated APLS as Equal-Weight on Jul 02, 2025, setting a price target of 26. Despite the Hold call, shares climbed 129.24% to 40.85, revealing unexpected momentum.

BPMC

Hold

Jun 05, 2025

Target

$129.00

Current

$129.46

Performance

1.22%

On Jun 05, 2025, BPMC was given a Equal-Weight rating by Judah Frommer, with a target price of 129. Market indecision, reflected in sideways trading near 129.46, supported the cautious call.

CLDX

Buy

Mar 20, 2025

Target

$46.00

Current

$33.33

Performance

67.66%

CLDX received a Overweight rating from Judah Frommer on Mar 20, 2025, aiming for 46. Momentum has favored the Buy call, with shares climbing from 33.33 to 33.33, rewarding those who trusted the recommendation.

GLPG

Sell

Feb 14, 2025

Target

$22.00

Current

$28.88

Performance

13.52%

On Feb 14, 2025, Judah Frommer published a Underweight outlook on GLPG, with a target of 22. Investors who followed the Sell rating avoided losses as the stock weakened.

FDMT

Sell

Jan 13, 2025

Target

$6.00

Current

$9.66

Performance

102.94%

Judah Frommer on Jan 13, 2025 assigned FDMT a Underweight rating, with a price target of 6. The market validated the bearish call with a pullback to 9.66.

BCAX

Buy

Oct 08, 2024

Target

$35.00

Current

$22.98

Performance

1.91%

On Oct 08, 2024, Judah Frommer reaffirmed BCAX with a Overweight rating, targeting 35. Market indecision has kept the 35 target in a holding pattern.

Frequency Asked Questions

Who is Judah Frommer?

Judah Frommer is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Judah Frommer's success rate?

Judah Frommer currently has a success rate of +69.53%.

How many ratings has Judah Frommer issued?

Judah Frommer has issued 19 stock ratings so far.

What is the average return of Judah Frommer's calls?

Their stock ratings have generated an average return of +19.57%.

What is Judah Frommer's ranking?

Judah Frommer is ranked #1960 out of 4620 analysts.

What types of ratings does Judah Frommer give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Judah Frommer?

You can follow Judah Frommer by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Judah Frommer?

Their latest rating was a Buy on KLRS issued on 2026-04-16.